Literature DB >> 26292615

Biliary complications of arterial chemoembolization of hepatocellular carcinoma.

E Dhamija1, S B Paul2, S R Gamanagatti1, S K Acharya1.   

Abstract

RATIONALE AND
BACKGROUND: Transarterial chemoembolization (TACE) is the most frequently used palliative therapy for unresectable hepatocellular carcinoma (HCC). It is a safe and effective procedure with few major and minor complications. Rarely, biliary complications are also encountered following TACE. The goal of our study was to investigate the incidence and the presentation of biliary complications following TACE in patients with HCC.
MATERIAL AND METHODS: In this retrospective study, data of patients with HCC who underwent TACE between June 2002 to December 2014 were obtained from the records. Their detailed information about the procedure of TACE, diagnosis of biliary complications and subsequent management details were reviewed. RESULT: One hundred and sixty-eight patients with HCC underwent 305 procedures of TACE. Of these, biliary complications of various severities developed in 6 (3.6%) patients leading to an incidence of 1.9% (6/305). Minimal intrahepatic biliary dilatation (IHBD) occurred in three, biliary stricture in one and intrahepatic biloma in two patients. Supportive management was undertaken for IHBD patients while percutaneous aspiration and naso-biliary drainage was performed for the infected bilomas.
CONCLUSION: Biliary complications following TACE are infrequent. Diagnosis should be suspected clinically and confirmed with imaging. Treatment depends on the severity. Enforcing specific measures can minimize its frequency.
Copyright © 2015 Éditions françaises de radiologie. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Biliary complications; Biloma; Hepatocellular carcinoma (HCC); Transarterial chemoembolization (TACE)

Mesh:

Year:  2015        PMID: 26292615     DOI: 10.1016/j.diii.2015.06.017

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  4 in total

1.  Predicting post-transarterial chemoembolization outcomes: A comparison of direct and total bilirubin serums levels.

Authors:  S Young; T Sanghvi; J J Lake; N Rubin; J Golzarian
Journal:  Diagn Interv Imaging       Date:  2020-01-13       Impact factor: 4.026

2.  Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres.

Authors:  Katharina Carolin Albrecht; René Aschenbach; Ioannis Diamantis; Niklas Eckardt; Ulf Teichgräber
Journal:  J Cancer Res Clin Oncol       Date:  2020-09-02       Impact factor: 4.553

3.  The feasibility of transcatheter arterial chemoembolization following radiation therapy for hepatocellular carcinoma.

Authors:  Mostafa Hamada; Eisuke Ueshima; Takeaki Ishihara; Yutaka Koide; Takuya Okada; Hiroki Horinouchi; Jun Ishida; Hiroshi Mayahara; Koji Sasaki; Tomoyuki Gentsu; Keitaro Sofue; Masato Yamaguchi; Ryohei Sasaki; Koji Sugimoto; Takamichi Murakami
Journal:  Acta Radiol Open       Date:  2021-08-04

4.  Infectious complications related to radiofrequency ablation of liver tumors: The role of antibiotics.

Authors:  Ryo Nakagomi; Ryosuke Tateishi; Shintaro Mikami; Taijiro Wake; Mizuki Nishibatake Kinoshita; Takuma Nakatsuka; Tatsuya Minami; Masaya Sato; Koji Uchino; Kenichiro Enooku; Hayato Nakagawa; Yoshinari Asaoka; Shuichiro Shiina; Kazuhiko Koike
Journal:  PLoS One       Date:  2021-11-19       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.